ArticleBMC health services research2022

Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.

Arjun Bhadhuri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.